Frequency of Thrombocytopenia and Heparin-Induced Thrombocytopenia in Patients Receiving Extracorporeal Membrane Oxygenation Compared With Cardiopulmonary Bypass and the Limited Sensitivity of Pretest Probability Score.


Journal

Critical care medicine
ISSN: 1530-0293
Titre abrégé: Crit Care Med
Pays: United States
ID NLM: 0355501

Informations de publication

Date de publication:
05 2020
Historique:
pubmed: 15 2 2020
medline: 20 5 2021
entrez: 15 2 2020
Statut: ppublish

Résumé

To ascertain: 1) the frequency of thrombocytopenia and heparin-induced thrombocytopenia; 2) positive predictive value of the Pretest Probability Score in identifying heparin-induced thrombocytopenia; and 3) clinical outcome of heparin-induced thrombocytopenia in adult patients receiving venovenous- or venoarterial-extracorporeal membrane oxygenation, compared with cardiopulmonary bypass. A single-center, retrospective, observational cohort study from January 2016 to April 2018. Tertiary referral center for cardiac and respiratory failure. Patients who received extracorporeal membrane oxygenation for more than 48 hours or had cardiopulmonary bypass during specified period. None. Clinical and laboratory data were collected retrospectively. Pretest Probability Score and heparin-induced thrombocytopenia testing results were collected prospectively. Mean age (± SD) of the extracorporeal membrane oxygenation and cardiopulmonary bypass cohorts was 45.4 (± 15.6) and 64.9 (± 13), respectively (p < 0.00001). Median duration of cardiopulmonary bypass was 4.6 hours (2-16.5 hr) compared with 170.4 hours (70-1,008 hr) on extracorporeal membrane oxygenation. Moderate and severe thrombocytopenia were more common in extracorporeal membrane oxygenation compared with cardiopulmonary bypass throughout (p < 0.0001). Thrombocytopenia increased in cardiopulmonary bypass patients on day 2 but was normal in 83% compared with 42.3% of extracorporeal membrane oxygenation patients at day 10. Patients on extracorporeal membrane oxygenation also followed a similar pattern of platelet recovery following cessation of extracorporeal membrane oxygenation. The frequency of heparin-induced thrombocytopenia in extracorporeal membrane oxygenation and cardiopulmonary bypass were 6.4% (19/298) and 0.6% (18/2,998), respectively (p < 0.0001). There was no difference in prevalence of heparin-induced thrombocytopenia in patients on venovenous-extracorporeal membrane oxygenation (8/156, 5.1%) versus venoarterial-extracorporeal membrane oxygenation (11/142, 7.7%) (p = 0.47). The positive predictive value of the Pretest Probability Score in identifying heparin-induced thrombocytopenia in patients post cardiopulmonary bypass and on extracorporeal membrane oxygenation was 56.25% (18/32) and 25% (15/60), respectively. Mortality was not different with (6/19, 31.6%) or without (89/279, 32.2%) heparin-induced thrombocytopenia in patients on extracorporeal membrane oxygenation (p = 0.79). Thrombocytopenia is already common at extracorporeal membrane oxygenation initiation. Heparin-induced thrombocytopenia is more frequent in both venovenous- and venoarterial-extracorporeal membrane oxygenation compared with cardiopulmonary bypass. Positive predictive value of Pretest Probability Score in identifying heparin-induced thrombocytopenia was lower in extracorporeal membrane oxygenation patients. Heparin-induced thrombocytopenia had no effect on mortality.

Identifiants

pubmed: 32058356
doi: 10.1097/CCM.0000000000004261
doi:

Substances chimiques

Anticoagulants 0
Heparin 9005-49-6

Types de publication

Journal Article Observational Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

e371-e379

Auteurs

Deepa R J Arachchillage (DRJ)

Department of Haematology, Royal Brompton Hospital, London, United Kingdom.
Department of Haematology, Imperial College Healthcare NHS Trust, London, United Kingdom.
Centre for Haematology, Department of Inflammation and Immunology, Imperial College London, London, United Kingdom.

Mike Laffan (M)

Department of Haematology, Imperial College Healthcare NHS Trust, London, United Kingdom.
Centre for Haematology, Department of Inflammation and Immunology, Imperial College London, London, United Kingdom.

Sanjay Khanna (S)

Department of Intensive Care Medicine, Royal Brompton & Harefield NHS Foundation Trust, London, United Kingdom.

Christophe Vandenbriele (C)

Department of Intensive Care Medicine, Royal Brompton & Harefield NHS Foundation Trust, London, United Kingdom.

Farah Kamani (F)

Department of Haematology, Royal Brompton Hospital, London, United Kingdom.

Maurizio Passariello (M)

Department of Intensive Care Medicine, Royal Brompton & Harefield NHS Foundation Trust, London, United Kingdom.

Alex Rosenberg (A)

Department of Intensive Care Medicine, Royal Brompton & Harefield NHS Foundation Trust, London, United Kingdom.

T C Aw (TC)

Department of Anaesthesia, Royal Brompton & Harefield NHS Foundation Trust, London, United Kingdom.

Winston Banya (W)

Department of Medical Statistics, Royal Brompton & Harefield NHS Foundation Trust, London, United Kingdom.

Stephane Ledot (S)

Department of Intensive Care Medicine, Royal Brompton & Harefield NHS Foundation Trust, London, United Kingdom.

Brijesh V Patel (BV)

Department of Intensive Care Medicine, Royal Brompton & Harefield NHS Foundation Trust, London, United Kingdom.
Department of Surgery & Cancer, Imperial College London, London, United Kingdom.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH